Biotech Industry Expected to Experience More M&A Activity in 2013
Five Star Equities Provides Stock Research on Amicus Therapeutics and Zalicus
NEW YORK, NY -- (Marketwire) -- 01/15/13 -- Lost revenues from expiring patents has played a major part in the Biotech Industry's success in recent years. A total of 676 takeovers of biotechnology and pharmaceutical companies have occurred in the past three years, with an average premium of 38 percent, according to data collected by Bloomberg. Five Star Equities examines the outlook for companies in the Biotech Industry and provides equity research on Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Zalicus Inc. (NASDAQ: ZLCS).
At the end of the third quarter five of the biggest drug makers in the U.S. held over $70 billion in cash, near cash and short-term investments. Major revenue losses from patent expirations have forced big pharmaceutical companies to look to biotech companies to help fill the void. Pfizer's Lipitor and Bristol-Myers' Plavix, which lost exclusivity in late 2011, had combined annuals revenues of $17 billion at their peaks.
"We're through many cost-cutting programs, restructurings and portfolio arrangements," said Henry Gosebruch, Managing Director, Mergers & Acquisitions J.P. Morgan. "When you put that together with record levels of cash available and improving, but still moderate R&D productivity, we think there will be more big pharma M&A activity in 2013."
Five Star Equities releases regular market updates on the Biotech Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports and industry newsletters.
Amicus Therapeutics is a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases. Amicus and GlaxoSmithKline are co-developing migalastat HCl for Fabry disease. The company believes its current cash position and anticipated Fabry program reimbursements from GSK will be enough to fund operations into the second half of 2014.
Zalicus has a portfolio of proprietary clinical-stage product candidates targeting pain, including Z160, an N-type calcium channel blocker for chronic neuropathic pain and Z944, a T-type calcium channel blocker for acute and inflammatory pain. The company has recently initiated the second of two Phase 2a clinical studies of Z160.
Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: